Junaid Syed, MD
Psychiatry · Saint Louis, MONPI 1942381579
Payments from drug & device makers
Across 895 payments — averaging $8909.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.8M
- E.r. Squibb & Sons, L.L.C.$1M
- Sumitomo Pharma America, Inc.$987K
- Eli Lilly$774K
- Sunovion Pharmaceuticals Inc.$360K
- plus $1.1M from 24 others
Across 27 payments — averaging $17,057 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$443K
- Eli Lilly$16K
- AbbVie$955
What the payments were for
- Travel & lodging$4,49242%
- Food & beverage$6,08857%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 202 | $1,922,550 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 81 | $1,807,164 |
| E.r. Squibb & Sons, L.L.C. | 18 | $1,032,089 |
| Sumitomo Pharma America, Inc. | 59 | $987,135 |
| Eli Lilly | 13 | $774,189 |
| Sunovion Pharmaceuticals Inc. | 27 | $360,361 |
| Alkermes, Inc. | 249 | $278,620 |
| AbbVie | 22 | $196,019 |
| Boehringer Ingelheim | 26 | $176,445 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $135,354 |
| Avanir Pharmaceuticals, Inc. | 38 | $117,151 |
| Sage Therapeutics, LLC | 15 | $64,774 |
| GW Research Limited | 8 | $37,119 |
| Roche TCRC, Inc. | 4 | $27,790 |
| Indivior Inc. | 12 | $24,033 |
| Vanda Pharmaceuticals Inc. | 8 | $15,101 |
| Boehringer Ingelheim RCV GmbH & Co KG | 15 | $14,373 |
| Jazz Pharmaceuticals Inc. | 1 | $1,012 |
| Johnson & Johnson(2 entities) | 30 | $669 |
| Neurocrine Biosciences, Inc. | 17 | $612 |
| Acadia Pharmaceuticals Inc | 11 | $439 |
| Otsuka America Pharmaceutical, Inc. | 7 | $230 |
| Lundbeck LLC | 5 | $119 |
| Biogen | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| UCB, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$940
- ARISTADA$480
- INGREZZA$265
- NUPLAZID$246
- INVEGA SUSTENNA$123
- INVEGA TRINZA$123
- INVEGA$123
- SPRAVATO$123
- UZEDY$121
- ARISTADA INITIO$120
- REXULTI$110
How this compares
$7,973,620 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 454 | $1,507,444 |
| IngrezzaValbenazine Tosylate | 148 | $727,945 |
| Invega TrinzaPaliperidone Palmitate | 24 | $211,069 |
| Risperdal ConstaRisperidone Microspheres | 162 | $200,708 |
| UzedyRisperidone | 41 | $134,172 |
| AustedoDeutetrabenazine | 19 | $110,069 |
| Abilify MaintenaAripiprazole | 34 | $101,200 |
| Clozapine OdtClozapine | 145 | $70,594 |
| Clozapine | 1,183 | $65,727 |
| VraylarCariprazine Hcl | 91 | $64,824 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $61,779 |
| Aripiprazole | 725 | $56,060 |
| Paliperidone ErPaliperidone | 373 | $55,260 |
| CaplytaLumateperone Tosylate | 32 | $54,117 |
| RexultiBrexpiprazole | 72 | $52,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $669 | $1,919,221640 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $612 | $727,945148 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo | $1,922,550 | $244,24160 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $230 | $153,716106 claims |
| Alkermes, Inc.Lybalvi, Aristada | $278,620 | $112,36453 claims |
| AbbVieVraylar | $196,019 | $64,82491 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,807,164 | $54,11732 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $13 | $42,9801,175 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $117,151 | $36,96232 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $360,361 | $29,25828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $20,67984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Asif HabibSaint Louis$517K
- Eric LenzeSaint Louis$271K
- Christopher LoyndSaint Louis$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.